Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosusLund Univ, Sweden.
Toronto Western Hosp, Canada; Univ Toronto, Canada.
Toronto Western Hosp, Canada; Univ Toronto, Canada.
Inst Nacl Ciencias Med and Nutr Salvador Zubiran, Mexico.
Hanyang Univ, South Korea.
Univ Laval, Canada.
Toronto Western Hosp, Canada; Univ Toronto, Canada.
Univ Calgary, Canada.
McGill Univ, Canada.
Univ Birmingham, England.
Queen Elizabeth 2 Hlth Sci Ctr, Canada; Queen Elizabeth 2 Hlth Sci Ctr, Canada; Dalhousie Univ, Canada.
Univ Calif Los Angeles, CA USA.
UCL, England.
UCL, England.
Oklahoma Med Res Fdn, OK 73104 USA.
Suny Downstate Med Ctr, NY 11203 USA.
Univ Alabama Birmingham, AL 35294 USA.
Univ Alabama Birmingham, AL 35294 USA.
Johns Hopkins Univ, MD USA.
Kings Coll London, England.
Feinstein Inst Med Res, NY USA.
Feinstein Inst Med Res, NY USA.
Univ N Carolina, NC 27515 USA.
Allegheny Hlth Network, PA USA.
Northwestern Univ, IL 60611 USA; Feinberg Sch Med, IL USA.
Lund Univ, Sweden.
Landspitali Univ Hosp, Iceland.
Hairmyres Hosp, Scotland.
Univ Basque Country, Spain.
Emory Univ, GA USA.
UCSD Sch Med, CA USA.
Istanbul Univ, Turkey.
Univ Amsterdam, Netherlands; Free Univ VU Amsterdam, Netherlands; Amsterdam Rheumatol and Immunol Ctr, Netherlands.
Hosp Clin Barcelona, Spain.
Med Univ South Carolina, SC 29425 USA.
Copenhagen Univ Hosp, Denmark.
Univ Manitoba, Canada.
Columbia Univ, NY USA.
Kantousspital, Switzerland.
Univ Manchester, England; Manchester Univ Hosp NHS Fdn Trust, England.
Visa övriga samt affilieringar
2020 (Engelska)Ingår i: Journal of Autoimmunity, ISSN 0896-8411, E-ISSN 1095-9157, Vol. 106, artikel-id 102340Artikel i tidskrift (Refereegranskat) Published
Abstract [en]
Objective
The soluble urokinase plasminogen activator receptor (suPAR) has potential as a prognosis and severity biomarker in several inflammatory and infectious diseases. In a previous cross-sectional study, suPAR levels were shown to reflect damage accrual in cases of systemic lupus erythematosus (SLE). Herein, we evaluated suPAR as a predictor of future organ damage in recent-onset SLE.
Methods
Included were 344 patients from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort who met the 1997 American College of Rheumatology classification criteria with 5-years of follow-up data available. Baseline sera from patients and age- and sex-matched controls were assayed for suPAR. Organ damage was assessed annually using the SLICC/ACR damage index (SDI).
Results
The levels of suPAR were higher in patients who accrued damage, particularly those with SDI≥2 at 5 years (N = 32, 46.8% increase, p = 0.004), as compared to patients without damage. Logistic regression analysis revealed a significant impact of suPAR on SDI outcome (SDI≥2; OR = 1.14; 95% CI 1.03–1.26), also after adjustment for confounding factors. In an optimized logistic regression to predict damage, suPAR persisted as a predictor, together with baseline disease activity (SLEDAI-2K), age, and non-Caucasian ethnicity (model AUC = 0.77). Dissecting SDI into organ systems revealed higher suPAR levels in patients who developed musculoskeletal damage (SDI≥1; p = 0.007).
Conclusion
Prognostic biomarkers identify patients who are at risk of acquiring early damage and therefore need careful observation and targeted treatment strategies. Overall, suPAR constitutes an interesting biomarker for patient stratification and for identifying SLE patients who are at risk of acquiring organ damage during the first 5 years of disease.
Ort, förlag, år, upplaga, sidor
Elsevier, 2020. Vol. 106, artikel-id 102340
Nyckelord [en]
Biomarker; SLE; Organ damage; Prognosis; Outcome
Nationell ämneskategori
Reumatologi och inflammation
Identifikatorer
URN: urn:nbn:se:liu:diva-163458DOI: 10.1016/j.jaut.2019.102340ISI: 000508747000012PubMedID: 31629628Scopus ID: 2-s2.0-85073722485OAI: oai:DiVA.org:liu-163458DiVA, id: diva2:1393702
Anmärkning
Funding Agencies|Swedish Rheumatism Association; Region Ostergotland (ALF Grants); King Gustaf Vs 80-year Anniversary Foundation; King Gustaf V and Queen Victorias Freemasons Foundation; Versus ArthritisVersus Arthritis; NIHR Manchester Biomedical Research CentreNational Institute for Health Research (NIHR); NIHR/Welcome Trust Manchester Clinical Research Facility; Lupus UK; Sandwell and West Birmingham Hospitals NHS Trust; National Institute for Health Research (NIHR)/Wellcome Trust Birmingham Clinical Research Facility; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [8UL1TR000150]; National Research Foundation of KoreaNational Research Foundation of Korea [NRF-2017M3A9B4050335]
2020-02-172020-02-172021-04-30Bibliografiskt granskad